[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,157,894
  • Shares Outstanding, K 98,489
  • Annual Sales, $ 673,000 K
  • Annual Income, $ -575,000 K
  • EBIT $ -561 M
  • EBITDA $ -530 M
  • 60-Month Beta 0.37
  • Price/Sales 3.41
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 58.97% (+0.31%)
  • Historical Volatility 45.83%
  • IV Percentile 49%
  • IV Rank 14.26%
  • IV High 187.31% on 12/26/25
  • IV Low 37.62% on 09/11/25
  • Expected Move (DTE 11) 1.53 (6.98%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 40
  • Volume Avg (30-Day) 1,133
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 29,168
  • Open Int (30-Day) 27,365
  • Expected Range 20.38 to 23.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.24
  • Number of Estimates 8
  • High Estimate $-1.16
  • Low Estimate $-1.30
  • Prior Year $-1.17
  • Growth Rate Est. (year over year) -5.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.33 +2.72%
on 06/02/26
27.42 -20.09%
on 05/11/26
-3.10 (-12.40%)
since 05/05/26
3-Month
18.29 +19.79%
on 03/24/26
27.42 -20.09%
on 05/11/26
+0.45 (+2.10%)
since 03/05/26
52-Week
18.29 +19.79%
on 03/24/26
42.37 -48.29%
on 07/09/25
-15.00 (-40.64%)
since 06/05/25

Most Recent Stories

More News
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

NEW YORK , June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ:...

RARE : 21.91 (-6.01%)
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 21.91 (-6.01%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 21.91 (-6.01%)
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 21.91 (-6.01%)
Ultragenyx: Q1 Earnings Snapshot

Ultragenyx: Q1 Earnings Snapshot

RARE : 21.91 (-6.01%)
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760...

RARE : 21.91 (-6.01%)
Ultragenyx's Conference Call Tomorrow: Still Waiting for Gene Therapy to Pay Rent

Barchart Research What to Expect from RARE Earnings RARE Generated May 4, 2026 Current Price $24.81 EPS Estimate $$-1.55 Consensus Rating Strong Buy Average Move 5.39% Ultragenyx's Conference Call Tomorrow:...

RARE : 21.91 (-6.01%)
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...

RARE : 21.91 (-6.01%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 21.91 (-6.01%)
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their...

RARE : 21.91 (-6.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 24.64
2nd Resistance Point 24.02
1st Resistance Point 22.97
Last Price 21.91
1st Support Level 21.30
2nd Support Level 20.68
3rd Support Level 19.63

See More

52-Week High 42.37
Fibonacci 61.8% 33.17
Fibonacci 50% 30.33
Fibonacci 38.2% 27.49
Last Price 21.91
52-Week Low 18.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.